Ultragenyx Pharmaceutical
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 months.
- Recent price momentum is -41.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 24.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 83.8% | Better than 93% |
| Operating margin | -79.5% | Better than 8% |
| Net margin | -85.4% | Better than 7% |
| Return on equity | -656.0% | Better than 1% |
| Return on invested capital | -435.1% | Better than 0% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -36.2% | Better than 13% |
| 6-month return | -29.5% | Better than 19% |
| 12-month return (ex latest month) | -53.4% | Better than 2% |
| Distance below 52-week high | 58.7% | Better than 12% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.5x | Better than 66% |
| Debt to assets | 2.3% | Better than 87% |
| Interest coverage | -8.2x | Better than 14% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 47.4% | Better than 26% |
| Upside to average target | 54.1% | Better than 69% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 17.22
- Open
- 16.94
- Day range
- 16.43 - 17.35
- Avg price
- 16.62
- Volume
- 3.01M
- Turnover
- 50.02M
- Turnover ratei
- 3.60%
- Volume ratioi
- 0.72
- Amplitudei
- 5.37%
- 52-week rangei
- 12.73 - 39.89
Valuation
- P/Ei
- -2.83
- P/E (TTM)i
- -3.19
- P/Bi
- -4.47
- EPSi
- -5.83
- Book value / shi
- -3.69
- Net profit
- -594.22M
- Net assets
- -376.00M
Share structure
- Market cap
- 1.68B
- Float capi
- 1.38B
- Shares out
- 101.92M
- Float sharesi
- 83.54M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
58.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.06M net over the window
Short interest
- Shares short
- 23.62M
- % of floati
- 23.96%
- Days to coveri
- 8.27
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Ultragenyx Pharmaceutical (RARE)?
Ultragenyx Pharmaceutical last traded at 16.48. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Ultragenyx Pharmaceutical's market cap?
About 1.68B.
What is the P/E ratio of Ultragenyx Pharmaceutical?
The trailing twelve-month P/E is -3.19. The Valuation tab shows it against the stock's own five-year range.
Does Ultragenyx Pharmaceutical pay a dividend?
Ultragenyx Pharmaceutical does not currently pay a regular dividend.
Is Ultragenyx Pharmaceutical a buy according to analysts?
The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 25.39, which implies 54.1% upside from the current price. This is not investment advice.
What is Ultragenyx Pharmaceutical's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Ultragenyx Pharmaceutical a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.
Ultragenyx Pharmaceutical discussion 0 comments